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 Background : Management of Cushing’s syndrome, that is, excess cortisol 
secretion, has undergone considerable advances since the pioneering 
studies by Harvey Cushing. Surgery is clearly first choice for all etiologies of 
Cushing’s syndrome, and medical therapy is largely administered in the 
interim between other therapeutic options. The limited use of medical 
therapy is a consequence of the lack of a truly efficacious compound to 
restrain adrenocorticotrophic hormone or cortisol secretion, but this will 
hopefully change in the near future as molecules developed over the 
past few years are tested.  Conclusion : This paper illustrates present and 
perspective medical treatments for Cushing’s syndrome. 
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 1.  Introduction 
 Cushing’s syndrome is a disease caused by different etiologies, has a fraught 
diagnostic work-up and one main treatment option, that is, surgery, with variable 
outcome. Etiology of endogenous hypercortisolism comprises adrenocorticotrophic 
hormone (ACTH)-dependent forms, represented by ACTH-secreting pituitary 
adenomas, also known as ‘Cushing’s disease’ (85%), and ectopic ACTH-secreting 
neuroendocrine tumors (15%), and ACTH-independent forms, that is, cortisol-
secreting adrenal adenomas, carcinomas or bilateral nodular hyperplasia, both 
congenital and acquired ( Table 1 ). Clinical features of these distinct etiologies 
overlap and the differential diagnosis, as well as the diagnosis of Cushing’s 
syndrome  per se , require a battery of hormonal measurements supported by 
imaging procedures  [1] . This review illustrates the advances in medical management 
of Cushing’s syndrome and perspectives offered by recent research. 
 2.  Therapeutic strategy in Cushing’s syndrome 
 Once the etiological diagnosis has been established, any given patient with 
Cushing’s syndrome is sent to the surgeon for removal of the causative lesion 
( Figure 1 )  [2,3] . Surgery is usually straightforward for benign adrenal lesions, 
whereas adrenal carcinomas, pituitary and extrapituitary ACTH-secreting lesions 
represent more complex issues. Adrenal carcinomas are highly malignant lesions 
with low survival rates, ameliorated by adjuvant therapy with mitotane and 
chemotherapy but still carrying an unfavorable prognosis. Pituitary surgery, aimed 
at removal of the ACTH-secreting adenoma, is the first-line therapy in Cushing’s 
disease and, because pituitary adenomas are visible at imaging in only in 60% of 
patients, often requires a thorough pituitary exploration. However, even at the 
hands of the most experienced neurosurgeon, remission barely reaches 80%  [4] , 
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thus one out of five patients will require further therapeutic 
maneuvers. In addition, some 20% of cured patients relapse, 
and they too will require further treatments. Options 
available to these patients include repeat pituitary surgery 
and radiation therapy (either radiosurgery or conventional 
pituitary irradiation)  [5] , but neither assures success in 
> 60% of patients, and, lastly, bilateral adrenalectomy. This 
latter approach has gained increasing acceptance since 
the advent of laparoscopic surgery, but leaves the patient 
dependent on lifelong steroid replacement therapy  [6] . 
During this often tortuous therapeutic itinerary, drugs 
can be administered to contain cortisol hypersecretion and 
the attendant clinical manifestations. Lastly, patients with 
ectopic ACTH secretion may present two orders of problems: 
the tumor might not be completely resectable or, a not 
so rare occurrence, be ‘occult’, that is, not identifiable  [7] . 
If surgery is not feasible or has failed, patients require 
adrenalectomy or medical therapy ( Figure 1 ). 
 3.  Medical treatment 
 Medical therapy, aimed at containment of excess cortisol 
secretion  [8] , is indicated in patients with Cushing’s 
syndrome of any etiology in whom surgery has failed or is 
not a viable treatment option ( Figure 1  ;  Table 2 ). The current 
treatment modality is inhibition of adrenal steroid synthesis 
with ketoconazole, an imidazole derivate, as the most widely 
used compound. Symptoms of cortisol excess can also be 
attenuated by interference with the tissue glucocorticoid 
receptor and, indeed, the antiprogestin RU486 has been 
used successfully in some cases. Although efficacious in all 
etiologies of Cushing’s syndrome, ketoconazole and RU486 
are targeted to downstream events and thus do not represent 
a causative approach to ACTH-dependent Cushing’s syndrome. 
The use of drugs aimed at blocking adrenal stimulation by 
illicit receptors is limited to isolated case reports  [9] . On the 
other hand, drugs aimed at controlling ACTH secretion by 
the pituitary or extrapituitary tumor, although theoretically 
preferable, have not proved fully satisfactory. All these 
compounds have been available for at least 10 years and 
 Table 1 . Etiology of Cushing’s syndrome. 
 ACTH-dependent causes 
Pituitary ACTH-secreting adenoma
Ectopic ACTH-secreting neuroendocrine tumors
 ACTH-independent causes 
Adrenal adenoma
Adrenal carcinoma
Bilateral adrenal hyperplasia:
Acquired with possible involvement of illicit receptors
Congenital: McCune-Albright syndrome, Carney’s complex
developments mostly concern the use of sister molecules, 
for example cabergoline in place of bromocriptine, or of 
analogues with different specificities, such as the case for 
somatostatin, which are providing promising results. In 
addition, experimental studies are paving the way to future 
medical therapies with compounds such as thiazolidinediones 
and retinoic acid. This treatise will begin with drugs useful 
for all etiologies of Cushing’s syndrome, then proceed to 
compounds specific to ACTH-dependent Cushing’s syndrome. 
 Among these pharmacological options, patients are usually 
started on one compound, for example, ketoconazole, 
metyrapone or mitotane according to each center’s preference 
and expertise, and, last but not least, drug availability. 
Etomidate is used only in severely ill patients who require 
immediate relief of symptoms. If single drug regimes prove 
unsatisfactory and other therapeutic options (i.e., surgery, 
radiation therapy) are still unavailable, then the addition of 
another drug may prove beneficial. Combination therapy 
with multiple adrenal steroid synthesis inhibitors offers the 
advantage of administering individual agents at lower doses, 
thereby reducing the risk of side effects. In the future, 
combined pituitary–adrenal blocking agents may become 
feasible as studies with cabergoline, somatostatin receptor 
agonists and other compounds yield convincing results. 
 3.1  Adrenal steroid synthesis inhibitors 
 These compounds are used primarily as antimycotics but 
share a common inhibitory activity on adrenal cytochrome 
P450 enzymes  [10] . Steroidogenesis, in fact, requires the 
sequential action of three P450 enzymes and a dehydrogenase 
( Figure 2 ) and the blockade of one or more is sufficient 
to impair cortisol secretion. Partial or total inhibition of 
cortisol ensues according to the strength of the blockade 
and, indeed, adrenal insufficiency often occurs with potent 
steroid synthesis inhibitors, for example, metyrapone, 
etomidate and mitotane. Rebound ACTH increase may 
attempt to overcome the blockade and the use of progressively 
increasing doses is a common occurrence. Alternatively, 
multiple drugs may be administered at lower doses in order 
to avoid side effects related to high doses of a single 
compound. Medical therapy is also used as an extra measure 
in patients with Cushing’s disease treated by radiation therapy 
and tapered over time as the full efficacy of radiation takes 
place. As mentioned above, few developments have occurred 
in the past few years with these drugs, with the exception of 
mitotane and etomidate. 
 3.1.1  Ketoconazole 
 Ever since the report by Sonino  [11] , the antimycotic 
ketoconazole has been used for containment of cortisol 
excess, and remains the most satisfactory drug for Cushing’s 
syndrome. Ketoconazole blocks the first and last steps 
of cortisol synthesis ( Figure 2 ), with an extra effect on 
17  α -hydroxylase. No overwhelming ACTH rebound occurs on 
ketoconazole, and this has been explained by an additional 
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inhibitory effect of ketoconazole on pituitary ACTH 
secretion  [12] . Indeed, in the authors’ experience, the effective 
dosage of ketoconazole is established after 2 – 3 weeks of 
treatment and maintained over time. A recent French 
retrospective study demonstrated normalization of urinary free 
cortisol (UFC) in 50% of patients treated with ketoconazole, 
accompanied by regression of some signs of hypercortisolism, 
such as hypertension, overweight and diabetes  [13] . Another 
nitromidazole derivate, fluconazole, has recently been used 
in an elderly patient with cortisol-secreting adrenal 
carcinoma and achieved normalization of cortisol excretion 
for > 18 months  [14] , pointing to the possible efficacy of 
other, similar compounds. 
 3.1.2  Metyrapone 
 Metyrapone represents an alternative first choice medical 
therapy for Cushing’s syndrome in some centers, but is not 
available worldwide. Both short-term and long-term treatments 
are efficacious, although most long-term reports in patients 
with Cushing’s disease are in association with pituitary 
irradiation  [15] . This drug has recently been used for control 
of hypercortisolism in pregnancy  [16] , McCune-Albright 
syndrome  [17] and severe ectopic ACTH syndrome  [18] . 
 3.1.3  Etomidate 
 Etomidate, an anesthetic, belongs to the older generation of 
steroid synthesis inhibitors but has experienced a renewed 
interest over the past few years. Indeed, an increasing number 
of papers have been published on the use of intravenous 
etomidate to correct severe symptoms of hypercortisolism, 
both as an emergency drug and for long-term treatment. 
Etomidate inhibits both 11 α -hydroxylase and 17 α -hydroxylase 
( Figure 2 ) and can normalize serum cortisol within 12 h  [19] . 
The advantages of etomidate are rapid reversal of 
hypercortisolism, intravenous administration – necessary for 
Etiologic diagnosis
Transsphenoidal
adenomectomy
Cushing’s
disease 
Ectopic ACTH
secretion
Adrenal
adenoma
Adrenal
carcinoma
Adrenal
hyperplasia
Tumor removal Monolateral
adrenalectomy 
Radical
surgery
Bilateral
adrenalectomy
Cure Cure CureCure Mitotane
Inoperable
failure
relapse
Repeat pituitary surgery
Pituitary radiation
Bilateral adrenalectomy
Medical therapy
Occult/inoperable
failure
relapse
Bilateral adrenalectomy
Medical therapy
+
 Figure 1 . Therapeutic strategies for Cushing’s syndrome. Treatment choices for each etiology of Cushing’s syndrome are shown. 
 Table 2 . Doses of drugs used for treatment 
of Cushing’s syndrome. 
 Steroid synthesis blocking agents 
Ketoconazole 200 – 1000 mg/day
Fluconazole 200 – 400 mg/day
Metyrapone 500 – 6000 mg/day
Etomidate 0.03 – 0.3 mg/kg/h
Trilostane 240 – 1400 mg/day
Aminoglutethimide 1 – 2 g/day
Mitotane 0.5 – 5 g/day
 Glucocorticoid receptor antagonist 
Mifepristone (RU486) 5 – 30 mg/kg/day 
(400 – 800 mg/day)
 Serotonin receptor antagonists 
Ketanserin 40 – 80 mg/day
Ritanserin 10 – 15 mg/day
Cyproheptadine 12 – 24 mg/day
 GABAergic agonists 
Sodium valproate 600 – 1000 mg/day
 Dopamine receptor agonists 
Bromocriptine 2.5 – 40 mg/day
Cabergoline 0.5 – 7 mg/week
 Somatostatin analogues 
Octreotide 100 – 200 µg/day
Octreotide LAR 30 mg/month
SOM230 (pasireotide) 1200 – 1800 µg/day
 PPAR- g agonists 
Rosiglitazone 8 – 16 mg/day
Pioglitazone 15 – 45 mg/day
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patients unable to take oral medication – and its hypnotic 
effect. Indeed, etomidate has been administered to sedate 
patients with severe psychosis  [20,21] . 
 Dosage of etomidate ranges from 1 – 3 mg/h, corresponding 
to the non-hypnotic 0.03 – 0.06 mg/kg/h range, to higher, 
sedative doses (0.2 – 0.3 mg/kg/h), which induce complete 
adrenal unresponsiveness to ACTH  [22] . Some authors 
initiated treatment with the higher dose then proceeded 
with lower doses  [19,23] , whereas others favored the opposite 
sequence  [24,25] . Steroid replacement therapy has to be 
instituted as soon as cortisol levels fall below the normal 
range in order to prevent an adrenal crisis. The effect of 
etomidate is self-limited and cortisol levels rise to pretreatment 
values within 24 h of drug withdrawal after short-term 
administration  [26] , whereas prolonged treatment may induce 
a more lasting adrenal suppression  [23] . Most studies report 
short-term treatment with etomidate (4 – 12 days) in order 
to contain severe symptoms and reduce surgical risks  [20,24,25] . 
Of interest, etomidate was administered for > 5 months to 
an intubated patient  [23] and even, briefly, to a child with 
Cushing’s disease  [25] . In summary, intravenous etomidate 
may be useful for severely ill patients or patients requiring 
parenteral drug administration. As only isolated studies 
report on its long-term use, other, more manageable drugs 
should be reinstated as soon as feasible. 
 3.1.4  Mitotane 
 In addition to interfering with cortisol synthesis, mitotane 
(i.e.,  o,p ’DDD) destroys adrenal cells and thus is usually 
used for treatment of adrenal cancer rather than benign 
Cushing’s syndrome. A most recent multi-center study 
demonstrated that adjuvant mitotane treatment at low 
doses (1 – 3 g/day) prolonged recurrence-free survival up to 
threefold in patients with adrenal carcinoma  [27] . Not all 
patients respond, however, possibly owing to the need 
for mitochondrial activation of  o,p ’DDD  [28] and to 
tumor secretory status. Indeed, non-cortisol-secreting adrenal 
carcinomas appear less favorably affected by mitotane than 
cortisol-secreting tumors  [29] . Mitotane has occasionally been 
used also in patients with ectopic ACTH secretion, Cushing’s 
disease and adrenal nodular hyperplasia  [30,31] , in one case 
for up to 18 years  [32] . Side effects, for example gastro-
intestinal and neurological complaints, hypercholesterolaemia, 
accumulation in adipose tissue, unpredictability of individual 
responses and the need for steroid replacement therapy 
mandate handling of mitotane by expert centers. Of note, 
17b-Hydroxysteroid
dehydrogenase
17a-Hydroxylase 17,20 Lyase
Cholesterol
Pregnenolone
Progesterone
Deoxycorticosterone
Corticosterone
18OH-Corticosterone
Aldosterone
17OH-Pregnenolone
17OH-Progesterone
11-Deoxycortisol
Cortisol
Cortisone
Dehydroepiandrosterone Androstenediol
Androstenedione Testosterone
Estrone Estradiol
Cholesterol
side chain
cleavage 
3b-Hydroxysteroid dehydrogenase 
21-Hydroxylase
11b-Hydroxylase
11b-Hydroxylase
18-Oxydase
11b-Hydroxysteroid dehydrogenase 
AromataseAminoglutethimide
Trilostane
Mitotane
Ketoconazole, etomidate
Aminoglutethimide
Mitotane, metyrapone
Ketoconazole, etomidate
Aminoglutethimide
Ketoconazole
 Figure 2 . Adrenal steroidogenesis and steroid synthesis inhibitors. Enzymes involved in adrenal steroid synthesis are shown in italic, 
drugs are underlined. Filled circles indicate blockade by a given compound. 
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severe pancytopenia and long QT syndrome have recently 
been reported in patients on mitotane  [30,33] . 
 3.1.5  Other adrenal blocking agents 
 Aminoglutethimide and trilostane warrant just a brief 
mention. These two adrenal synthesis inhibitors have been 
used in the past in a few cases  [10] , alone or together 
with other adrenal blocking agents. The risk of adrenal 
insufficiency is high and side effects may mar the efficacy of 
these drugs, thus their use is limited. 
 3.2  Glucocorticoid receptor blockers 
 The progesterone and glucocorticoid receptor antagonist 
mifepristone (RU486) was proposed in the 1980s for patients 
with Cushing’s syndrome as blockade of the glucocorticoid 
receptor appeared a rational approach to treatment of 
hypercortisolism. However, the theoretical risk of adrenal 
insufficiency hampered its use and the drug never 
underwent formal clinical trials. Indeed, a recent paper 
reviews its use and found only 18 patients, mostly with 
ectopic ACTH secretion or adrenal carcinoma  [34] . Clinical 
improvement was reported in most, although symptoms of 
adrenal insufficiency, for example nausea, hypoglycemia, 
hypotension and even adrenal crisis, developed in some  [35] . 
Expert monitoring of patients treated with RU486 is 
necessary given its long half-life and the absence of specific 
markers of peripheral glucocorticoid activity. On balance, 
this drug awaits prospective clinical trials for its full efficacy 
and/or side effects to be established. 
 3.3  Neurotransmitters and neuromodulators 
 3.3.1  Serotonin antagonists 
 Serotonin antagonists have been used in the past to restrain 
tumoral ACTH secretion with mostly anecdotal results. 
Indeed, although  in vitro evidence indicates a direct 
inhibitory action of cyproheptadine, a competitive serotonin 
and histamine receptor blocker, on ACTH secretion by 
human corticotroph cells  [36,37] , only individual cases 
of long-term remission on cyproheptadine have been 
reported  [38,39] , in some case persisting even after drug 
withdrawal  [40] . Newer, more selective and long-acting 
serotonin receptor antagonists have been developed, but 
efficacy in Cushing’s disease remains inconsistent. Indeed, 
ketanserin and ritanserin induced stable improvement in 
only 3 out of 11 patients with Cushing’s disease  [41] . A 
unique use of serotonin antagonists could be inhibition of 
excess cortisol secretion in patients with adrenal hyperplasia 
expressing ectopic serotonin receptors  [9] , but selective 
antagonists for serotonin receptor subtypes 4 and 7, the 
most frequently expressed receptors  [42,43] , have yet to be 
tested in this condition. 
 3.3.2  GABAergic compounds 
 Evidence on the possible efficacy of sodium valproate, an 
enhancer of GABAergic neurotransmission and inhibitor of 
ACTH secretion by rat anterior pituitary cultures  [44] , in 
Cushing’s disease dates back several years and is limited to 
isolated reports  [45] . Beneficial effects have also been reported 
in patients treated with sodium valproate and steroid synthesis 
blocking agents, but efficacy is by and large limited  [46] . 
 3.3.3  Dopamine agonists 
 Dopamine is a direct inhibitor of ACTH secretion by 
human corticotroph cells  [37] and, indeed, several studies 
have investigated the therapeutic potential of bromocriptine, a 
preferential dopamine receptor 2 agonist, in Cushing’s disease. 
However, results were disappointing and < 10% of patients 
achieved a reduction in ACTH and cortisol secretion  [47] . 
Uninspiring results were also obtained with the depot 
bromocriptine formulation  [48] and escape frequently 
occurred even in patients in whom bromocriptine appeared 
to be clinically effective  [49] . The drug has not been 
completely abandoned, however, as beneficial effects on 
ACTH and cortisol secretion as well as amelioration of 
oculomotor movements have been reported just recently  [50] . 
Further, recent studies with cabergoline, a long-acting 
dopamine receptor 2 agonist, yielded promising results, 
with a marked decrease in ACTH and cortisol observed in 
6 out of 10 patients with Cushing’s disease on 1 – 2 mg/week 
cabergoline for 3 months  [51] . Responsiveness to cabergoline 
was associated with dopamine receptor 2 expression and binding 
in the tumor, which occurred in 15 out of 20 tumoral 
specimens  [51] . Subsequent studies with higher cabergoline 
doses (up to 7 mg/week) or for longer periods of time 
(up to 1 year) have been presented in poster format, and 
responsiveness to cabergoline ranges from 40 to 70%  [52,53] . 
Treatment with cabergoline also led to shrinkage of an 
ACTH-secreting pituitary macroadenoma  [54,55] , in keeping 
with the pro-apoptotic effect of dopamine agonists on 
tumoral corticotrophs  [56] and the ability of these compounds 
to alter blood flow within the tumor  [57] . Dopamine 
agonists also inhibit proliferation and ACTH synthesis by 
small cell lung cancer cell lines  [58,59] , possibly again by 
means of the type 2 receptor  [60] , which has led to their use 
in patients with ectopic ACTH secretion. Treatment with 
either bromocriptine  [61,62] or cabergoline  [60] yielded mostly 
transitory benefits, although one patient maintained normal 
adrenocortical function on bromocriptine for 4 years  [62] . 
Except for individual cases of peculiar sensitivity to 
dopamine agonists, however, escape from the suppressive 
effect is common and limits the long-term usefulness 
of these drugs to a few, responding patients. A cautionary 
note has arisen from recent reports on increased cardiac 
valve disease in patients with Parkinson’s disease on 
cabergoline  [63] . It should be noted, however, that Parkinson’s 
disease requires considerably higher doses than any attempted 
so far in Cushing’s disease (on average 3.6 mg/day) and that 
no patient treated with a total cabergoline dose < 1 g was 
found to have significant valve regurgitation  [64] . According 
to a rough estimate, therefore, an increased risk of cardiac 
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valve disease would occur in patients taking 1 mg cabergoline 
daily for at least 3 years; long-term risk-assessment studies 
on cabergoline administration to patients with Cushing’s 
disease are needed should the drug prove useful at high 
dose regimens. 
 3.3.4  Somatostatin and somatostatin analogues 
 Somatostatin, a brain-gut peptide that inhibits the secretion 
of several hormones, most notably growth hormone (GH) 
and insulin, has in the past been tested as a potential inhibitor 
of ACTH secretion, with variable results. Solid experimental 
evidence had accrued in the 1980 – 90s demonstrating that 
somatostatin inhibits ACTH secretion  [65,66] , and these 
results have been substantiated by recent findings on 
somatostatin or somatostatin receptor knockout mice 
displaying increased pituitary synthesis and secretion of 
ACTH  [67,68] . Clinical studies, however, failed to demonstrate 
efficacy of somatostatin or octreotide, the only available 
somatostatin analogue at the time, in patients with 
Cushings’s disease  [69,70] . Detailed  in vitro studies revealed 
that octreotide reduces ACTH secretion by tumoral 
corticotropes but that this effect is abolished by co-incubation 
with glucocorticoids, thus explaining the discrepancy 
between  in vivo and  in vitro findings in patients with 
Cushing’s disease  [70-72] . Accordingly, a reduction in ACTH 
levels was observed in adrenalectomized patients with 
rapidly growing pituitary corticotrope tumors, that is, 
Nelson’s syndrome, treated with octreotide  [69] . Somatostatin 
and octreotide both proved capable of inhibiting ACTH 
secretion by ectopic ACTH-secreting tumors  [73,74] , in 
keeping with the inhibitory action of somatostatin in 
neuroendocrine-secreting tumors. Long-term octreotide 
formulation as well as lanreotide, a somatostatin receptor 2 
agonist with longer half-life, have also been administered with 
success to patients with ectopic ACTH secretion  [75,76] . 
 The development of newer, differently selective somatostatin 
receptor agonists over the last few years has revived interest 
in this issue and, indeed, yielded promising results. One of 
the first new somatostatin receptor agonists, SOM230 or 
pasireotide, interacts with all somatostatin receptor subtypes 
except subtype 4 and shows the highest affinity for receptor 
type 5  [77] .  In vitro studies have shown that SOM230 inhibits 
ACTH release and cell proliferation in human corticotroph 
tumors  [71,78] and that this effect is mediated by the 
somatostatin type 5 receptor. This receptor subtype is the 
most abundant in corticotroph tumors  [71] and, unlike 
receptor type 2, is not suppressed by glucocorticoids  [71,72] . 
These findings may explain the lack of efficacy of octreotide 
in Cushing’s disease, as it acts preferentially on somatostatin 
type 2 receptors. On the other hand, recent experiments on 
murine tumoral corticotrophs revealed a functional interaction 
between somatostatin receptors type 5 and type 2  [79] . 
Further experimental evidence emphasized this concept as 
SOM230 inhibited basal and CRH-stimulated ACTH 
release with greater potency than BIM23268, a selective 
type 5 somatostatin receptor agonist  [78] . Further, SOM230 
prevented the increase in pituitary mitotic activity induced 
by adrenalectomy  [80] and was far more potent than 
octreotide in blunting  in vivo CRH-stimulated ACTH and 
corticosterone secretion  [81] . Studies in other pituitary tumors 
revealed that SOM230 also affects vascular endothelial 
growth factor secretion  [82] , MAPK pathway  [83] , and 
can induce tumor regression in transgenic mice bearing 
mammosomatotroph tumors  [84] . Clinical studies are as yet 
in Phase II, but appear promising. Indeed, preliminary data 
on 27 patients with Cushing’s disease treated with 600 µg 
pasireotide twice a day for 2 weeks showed reductions in 
UFC in 9 patients and normalization in 4  [85] . 
 Other somatostatin analogues targeted to single somatostatin 
receptor subtypes are being developed and await testing on 
corticotroph adenomas. Agonists such as BIM23268, which 
is selective for somatostatin receptor 5, might prove extremely 
interesting in view of the prominent role of this receptor 
subtype in controlling ACTH release  [68,72] . In alternative, 
antitumor somatostatin analogues such as TT-232, which 
are capable of controlling intracellular proliferative signals 
and inducing apoptosis, are promising candidates for 
neuroendocrine malignancies  [86] . 
 3.3.5  Somatostatin/dopamine receptor agonist 
chimeras 
 A new avenue for research is somatostatin–dopamine agonist 
chimeras that unite the two inhibitory mechanisms 
discussed above. Only limited  in vitro data are available for 
these agents and, to the best of the authors’ knowledge, no 
study on actively secreting corticotroph tumors has been 
published so far. A somatostatin–dopamine chimera acting 
on the somatostatin type 2 receptor as well as the dopamine 
type 2 receptor has been tested in two silent corticotroph 
tumors and reduced cell viability in one but not the other 
specimen  [87] . In human GH or prolactin-secreting tumors, 
the chimeric ligand appeared more potent than either 
somatostatin or dopamine analogues alone  [88] , in keeping 
with the enhanced functional activity of somatostatin–
dopamine receptor heterodimers  [89] . No patient has yet 
been tested with these chimeras, but proof of concept can 
be gained by the patient with an atypical lung carcinoid 
causing Cushing’s syndrome in whom combined treatment 
with lanreotide and cabergoline proved superior to either 
drug alone  [90] . 
 3.3.6  Somatostatin radiolabeled therapy 
 One alternative approach to ectopic Cushing’s syndrome or 
huge pituitary corticotroph adenomas is peptide receptor 
radionuclide therapy. Somatostatin analogues labeled with 
 β -emitting isotopes, such as  90 Y or  177 Lu, and infused 
intravenously can deliver high dose radiation to tumor cells 
by means of endocytosis of the somatostatin analogue by its 
receptor  [91] . Clinical trials with  90 Y-DOTA-Tyr 3 octreotide 
( 90 Y-DOTATOC) yielded favorable results in patients with 
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inoperable or disseminated neuroendocrine tumors, as did 
those with  177 Lu-DOTA-Tyr 3 octreotate ( 177 Lu-DOTATATE), 
a newer somatostatin analogue with higher affinity for 
the somatostatin type 2 receptor  [92] . Most recently, 
peptide receptor radionuclide therapy with both analogues 
was attempted in a patient with ectopic ACTH secretion 
due to a pancreatic, metastasized neuroendocrine tumor 
resulting in long-term regression of hormonal hyper-
secretion and clinical features and shrinkage of tumor 
and metastases  [93] . 
 3.4  New compounds 
 In the past few years, experimental studies have identified 
two new classes of agents for treatment of Cushing’s disease, 
namely retinoic acid and peroxisome proliferator-activated 
receptor (PPAR) gamma agonists. Only PPAR- γ agonists 
have been tested so far in patients with variable results and 
new compounds remain an active venue of research. 
 3.4.1  PPAR- g agonists 
 PPAR- γ is part of a nuclear receptor family involved in 
several actions, including adipose tissue differentiation, lipid 
and glucose metabolism, inflammation and tumorigenesis. 
Its interest in Cushing’s disease arose from the breakthrough 
study at Cedars-Sinai showing that thiazolidinediones (i.e., 
exogenous PPAR- γ ligands) exert an antiproliferative and 
pro-apoptotic effect on murine tumoral corticotrophs  [94] . 
Indeed, the development of tumor implants was prevented 
in mice treated with the thiazolidinedione rosiglitazone  [94] . 
This evidence led to clinical trials with rosiglitazone or its 
sister compound, pioglitazone, but results in humans were 
less striking than in mice. In fact > 30 patients have been 
tested with either compound and significant decreases in 
UFC, cortisol or ACTH have been registered only in a 
minority of patients  [95-100] . The timing of pituitary–adrenal 
responsiveness to PPAR- γ agonists is also individualized, 
with some patients presenting a decrease in UFC within 
2 – 3 months of treatment  [95,97] and others developing 
later responses  [98,99] . Escape from the suppressive effect 
has also been reported  [98] . On balance, clinical results 
were disappointing compared with the expectations stirred 
by animal studies, possibly a consequence of the different 
proliferative potential of murine and human tumoral 
corticotrophs and the low expression PPAR- γ receptors in 
the nucleus of human pituitary cells  [101] . Thiazolidinediones 
might also exert their antiproliferative action independently 
of the PPAR- γ receptor  [101] . Rosiglitazone has also 
been administered to a few patients with expanding 
pituitary tumors (i.e., Nelson’s syndrome and macro-
adenomas), again without significant decreases in ACTH 
secretion  [97,102,103] . Of note, some patients on rosiglitazone 
reported clinical improvement in addition to amelioration of 
insulin sensitivity  [95,96] , thus PPAR- γ agonists may prove 
useful as adjuvant therapy in some cases. Overall, beneficial 
effects of PPAR- γ agonists appear limited so far. 
 3.4.2  Retinoic acid 
 The potential efficacy of retinoic acid in Cushing’s disease is 
even greater than that of PPAR- γ agonists, as it has been 
shown to prevent synthesis and secretion of ACTH by both 
human and murine tumoral corticotrophs, in addition to its 
antiproliferative effect on these same cells  [104,105] . The use 
of this drug appears most advantageous as these effects were 
observed only in tumoral corticotrophs; indeed, normal 
pituitary corticotrophs present a pattern of transcription 
factors that does not allow retinoic acid to inhibit ACTH 
synthesis/secretion  [104] . So far, retinoic acid has been 
administered only to dogs with Cushing’s disease, with 
remarkable results, including reduction in ACTH and 
urinary cortisol concentrations, shrinkage of the pituitary 
tumor and improvement of clinical signs and survival 
times  [106] . Both retinoic acid receptor isoforms are expressed 
in ACTH-secreting tumors  [107] , thus the rationale for 
attempting retinoic acid administration in human Cushing’s 
disease is sound. 
 4.  Conclusion 
 Nearly 100 years have passed since the first description of 
Cushing’s syndrome by Harvey Cushing but therapeutic 
management of his namesake syndrome is still not fully 
satisfactory. In fact, only a few viable medical agents 
are available at present for patients who fail at first choice 
treatment, that is, surgery, or relapse. The mainstay remain 
steroidogenesis inhibitors, chiefly ketoconazole, but the impetus 
provided by studies in the past few years will hopefully pave 
the way to better and more specific treatments. 
 5.  Expert opinion 
 Treatment of Cushing’s syndrome, particularly medical 
therapy, continues to challenge even the most skilled 
endocrinologist. The advances that occurred in the 
recent past, however, justify a more optimistic outlook 
into the future; indeed, the intense interactions between 
endocrine centers all over the world now enables a 
more judicious choice among available therapeutic options. 
Accordingly, surgery, radiation and medical therapy are being 
used with increasingly better results. 
 Although steroid synthesis inhibitors, foremost ketoconazole, 
continue to be the more widely used pharmacological tool 
for Cushing’s syndrome, new, selectively targeted compounds 
are under investigation and are yielding encouraging results. 
More potent and at the same time more manageable molecules 
for a temporary or permanent chemical adrenalectomy will 
become available, to be used chiefly in primary adrenal 
hypercortisolism. On the other hand, the possibility 
of blocking ACTH secretion in patients with Cushing’s 
disease and, hopefully, also in patients with neuroendocrine 
ACTH-secreting tumors, is rapidly approaching. Newer 
dopamine receptor agonists at high doses, such as 7 mg/week 
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cabergoline, have been tested in small groups of patients 
with Cushing’s disease and achieved reduction/normalization 
in UFC secretion in 40 – 70% of patients. Even long-lasting 
remissions while on cabergoline have been reported. Along 
the same line, recently developed somatostatin receptor 
ligands are proving beneficial in patients with Cushing’s 
disease. One such compound, SOM230 or pasireotide, a 
somatostatin multireceptor ligand, is now in a Phase II multi-
center international study and appears to reduce/normalize 
UFC in up to 50% of patients with Cushing’s disease. The 
development of chimeric dopamine–somatostatin receptor 
ligands is an obvious progression that is already underway. 
Somatostatin ligands are also ideal candidates for peptide 
receptor radionuclide therapy and isotopes can thus deliver 
concentrated radioactivity to neuroendocrine cells, both outside 
and within the pituitary. The use of PPAR- γ agonists in 
Cushing’s disease has strong experimental support and, 
although results obtained so far with rosiglitazone and 
pioglitazone are not fully satisfactory, further studies could 
provide more effective molecules. Similar considerations 
apply to retinoic acid, which has yielded spectacular results 
in animals but has not been investigated as yet in man. 
 In summary, medical therapy together with surgery and 
radiation therapy have significantly improved the outcome 
for patients with Cushing’s syndrome. The near future will 
probably see further progress in the tools available to cure 
this severe endocrine disorder. 
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